<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-15.7'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//valuedeepdive.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://valuedeepdive.com/sam-chun-dang-pharm-s-pass-glp1-analysis/</loc>
  <lastmod>2026-04-10T14:31:05Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>ValueDeepDive</news:name>
    <news:language>ko</news:language>
   </news:publication>
   <news:title>삼천당제약 S-PASS, 위고비를 ‘알약’으로? 100조 시장 뒤집을 수 있을까</news:title>
   <news:publication_date>2026-04-10T14:31:02Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://valuedeepdive.com/hyundai-enc-vs-samsung-cnt-valuation/</loc>
  <lastmod>2026-04-08T07:20:27Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>ValueDeepDive</news:name>
    <news:language>ko</news:language>
   </news:publication>
   <news:title>현대건설 18만 원 돌파, ‘거품’인가 ‘혁명’인가? (삼성물산의 숫자가 말하는 진실)</news:title>
   <news:publication_date>2026-04-08T07:20:25Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
